Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?

Nature Clinical Practice Oncology volume 2, pages 498–499 (2005)Cite this article

boxed-textDowsett M et al. (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23: 2477–2492

These results will not currently affect the selection of endocrine therapy for breast cancer, but prove the feasibility of paired biopsies in the neoadjuvant setting to test hypotheses and new agents

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Early Breast Cancer Trialists' Collaborative Group. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

  2. Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139

    Article  CAS  Google Scholar 

  3. Ellis M et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ERB-1 and/or Erb-2 positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 19: 3808–3816

    Article  CAS  Google Scholar 

  4. Osborne CK et al. (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11(Pt 2): 865s–870s

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Assistant Attending Physician on the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Maura Dickler

Authors
  1. Maura Dickler
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Dr Dickler participates in an AstraZeneca Speakers' Bureau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dickler, M. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?. Nat Rev Clin Oncol 2, 498–499 (2005). https://doi.org/10.1038/ncponc0298

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0298

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing